Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Non-Warfarin Oral Anticoagulants in Anti-Phospholipid Syndrome

Paul Kunk, MD, B. Gail Macik, MD, Melissa Rice, MD

Blood (2015) 126 (23): 1133.

https://doi.org/10.1182/blood.V126.23.1133.1133

Published: 2015

Journal Articles

Non-Warfarin Oral Anticoagulants in Heparin-Induced Thrombocytopenia

Paul Kunk, MD, B. Gail Macik, MD, Jacqueline Brown, MD

Blood (2015) 126 (23): 3547.

https://doi.org/10.1182/blood.V126.23.3547.3547

Published: 2015

Journal Articles

Long-Term Efficacy and Safety of Romiplostim Treatment of Adult Patients with Chronic Immune Thrombocytopenia (ITP): Final Report from an Open-Label Extension Study

David J. Kuter, MD, DPhil, James B. Bussel, MD, Adrian Newland, FRCP, Jeffrey S. Wasser, MD, Roger M Lyons, MD, James N. George, MD, Gail Macik, MD, Kun Nie, Susie Jun

Blood (2010) 116 (21): 68.

https://doi.org/10.1182/blood.V116.21.68.68

Published: 2010

Journal Articles

The Effects of Romiplostim or Standard of Care (SOC) on Splenectomy and Treatment Failure of Patients Who Had Immune Thrombocytopenia (ITP) for Less Than or Equal to One Year.

Ralph Boccia, MD, David J. Kuter, MD, DPhil, Mathias J. Rummel, MD, PhD, B. Gail Macik, MD, Ingrid Pabinger, MD, Dominik Selleslag, MD, Francesco Rodeghiero, MD, Beng Chong, MBBS, PhD, Xuena Wang, PhD, Richard Lizambri, MD

Blood (2010) 116 (21): 3702.

https://doi.org/10.1182/blood.V116.21.3702.3702

Published: 2010

Journal Articles

Home Administration of Romiplostim by Patients with Chronic Immune Thrombocytopenia (ITP).

Roger M Lyons, Ralph V. Boccia, MD, Gail Macik, MD, Romeo A. Mandanas, MD, FACP, Xuena Wang, Richard Lizambri, MD, Dietmar Berger, MD, PhD

Blood (2009) 114 (22): 3510.

https://doi.org/10.1182/blood.V114.22.3510.3510

Published: 2009

Journal Articles

Comparison of Splenectomy and Treatment Failure Incidence in Nonsplenectomized Patients with Immune Thrombocytopenia (ITP) Receiving Romiplostim or Medical Standard of Care: 1-Year Treatment and 6-Month Safety Follow-up.

David J Kuter, MD, DPhil, Mathias J Rummel, MD, PhD, Ralph Vincent Boccia, MD, B. Gail Macik, MD, Ingrid Pabinger, Dominik L.D. Selleslag, MD, Francesco Rodeghiero, Beng H Chong, MBBS, PhD, H. Müller-Beiβenhirtz, Lara Gehl, Xuena Wang, Dietmar Berger, MD, PhD

Blood (2009) 114 (22): 679.

https://doi.org/10.1182/blood.V114.22.679.679

Published: 2009

NARROW

Non-Warfarin Oral Anticoagulants in Anti-Phospholipid Syndrome

Non-Warfarin Oral Anticoagulants in Heparin-Induced Thrombocytopenia

Long-Term Efficacy and Safety of Romiplostim Treatment of Adult Patients with Chronic Immune Thrombocytopenia (ITP): Final Report from an Open-Label Extension Study

The Effects of Romiplostim or Standard of Care (SOC) on Splenectomy and Treatment Failure of Patients Who Had Immune Thrombocytopenia (ITP) for Less Than or Equal to One Year.

Home Administration of Romiplostim by Patients with Chronic Immune Thrombocytopenia (ITP).

Comparison of Splenectomy and Treatment Failure Incidence in Nonsplenectomized Patients with Immune Thrombocytopenia (ITP) Receiving Romiplostim or Medical Standard of Care: 1-Year Treatment and 6-Month Safety Follow-up.

Email alerts

ASH Publications

American Society of Hematology

Non-Warfarin Oral Anticoagulants in Anti-Phospholipid Syndrome

Non-Warfarin Oral Anticoagulants in Heparin-Induced Thrombocytopenia

Long-Term Efficacy and Safety of Romiplostim Treatment of Adult Patients with Chronic Immune Thrombocytopenia (ITP): Final Report from an Open-Label Extension Study

The Effects of Romiplostim or Standard of Care (SOC) on Splenectomy and Treatment Failure of Patients Who Had Immune Thrombocytopenia (ITP) for Less Than or Equal to One Year.

Home Administration of Romiplostim by Patients with Chronic Immune Thrombocytopenia (ITP).

Comparison of Splenectomy and Treatment Failure Incidence in Nonsplenectomized Patients with Immune Thrombocytopenia (ITP) Receiving Romiplostim or Medical Standard of Care: 1-Year Treatment and 6-Month Safety Follow-up.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only